Gijón, Spain, September 23rd 2024 – Microviable Therapeutics, a biotech company developing novel biological drugs for infectious diseases and oncology, announced today the appointment of Mehdi Chouikh Skalli as Chief Financial Officer.
Mehdi Chouikh has more than 20 years of experience in strategic management and financial direction, with a track record of success managing top class companies from conception to company acquisitions. Mehdi has been an entrepreneur with the incorporation of several companies successfully, and he is also an investor in a large number of companies from various sectors including biotech. Mehdi is a Telecommunications Engineer (2002, University of Málaga) with a Master in Management of Biotech Companies (2010, ESESA).
“I am thrilled to welcome Mehdi Chouikh into the executive team”, said Claudio Hidalgo, Ph.D., co-founder and CEO of Microviable. “The expertise Mehdi provides is crucial for our next steps of growth, including financial strategy and investor relationship”.
About Microviable Therapeutics
Microviable is a biotech company at preclinical stage developing novel biological drugs based on living bacteria, for infectious diseases and oncology. The company´s assets are orally delivered capsules containing living bacteria from the gut microbiome; MVT-201 has finalized preclinical phase in MDR-infectious diseases, and MVT-2401 is under preclinical testing for oncology. Microviable’s platform, encompassing bioinformatics, microbiology and immunology, together with a large and diverse proprietary bacterial culture collection has enabled the development of these novel assets, together with the growing intellectual property portfolio.
Contact:
info@microviable.co
